Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-02T19:40:55.520Z.
Calculation as of: 2026-10-02T19:40:55.520Z.
Quote observation: 2026-10-02T19:40:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a42e17afc1a1b5c0c05c4bcc318afc1e85bdb01f5d7a677422ba224d703768eb
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Recursion Pharmaceuticals, Inc. (RXRX) | $2.14B | N/A | N/A | N/A | N/A |
| Beam Therapeutics Inc. (BEAM)vs › | $2.51B | N/A | N/A | N/A | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.73B | N/A | 23.72 | 50.63 | 57.39 |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.72B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.74B | 20.52 | 34.18 | 472.96 | 472.96 |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $472.39M | N/A | 138.05 | 184.03 | 168.06 |
| NRC Health (NRC)vs › | $459.30M | 80.74 | 41.08 | 28.16 | 28.99 |
| Shoulder Innovations, Inc. (SI)vs › | $397.55M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $41.03M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$4.08
Forward EPS (Est.)
$-0.90
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
